Next 10 |
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Soros' 13F portfolio value increased from $4.08B to $5.30B this quarter. The number of positions increased from 132 to 146. Soros added Clarivate plc and Elanco Animal Health while dropping DraftKings and E*TRADE Financial. Liberty Broadband at ~16% of the portfolio is by far the ...
Tudor Investment reported total fund portfolio value of $2.3B in its recent 13F filing a marginal growth from $2.02B in the previous quarter.Notable buys include Clean Energy Fuels (CLNE), First Solar (FSLR), Ford Motor (F), Hecla Mining (HL), DropBox (DBX), ADT (ADT) and Immunomedics (IMMU)....
Prem Watsa’s 13F portfolio value increased from $1.59B to $1.77B this quarter. Fairfax Financials’ largest three stakes are Atlas Corp., BlackBerry, and Kennedy-Wilson. They together account for ~73% of the 13F assets. The 13F securities form a small portion of their...
Soros's 13F portfolio value decreased from $4.48B to $4.08B this quarter. The number of positions decreased from 141 to 132. Soros added Palantir Technologies and Unity Software, while reducing T-Mobile US. Also, most of their recent additions in Financials were either reduced or elim...
GILD reports earnings after-hours. Remdesivir could revive growth in the short term. However, revenue from HIV and HCV could be dead for now. GLPG's R&D pipeline has suffered some setbacks and may not be the boon GILD once thought. The IMMU deal could limit GILD's ability ...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
The best sectors to focus your attention on now. The highest-rated stocks worth adding to your watch list. Why high-volatility ahead of elections could create a great buy opportunity. For further details see: If Stocks Tumble On Election Worries, Here Are The Top Stocks ...
Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information. This can't come to much of a surprise to investors, as Iovance's TIL therapy carries a complex manufacturing and ...
As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...